BioAge Labs (BIOA)

Executive Summary

BioAge Labs is a clinical-stage biotechnology company leveraging its proprietary human-first discovery platform to develop therapies at the intersection of aging biology and metabolic disease. The company's lead program targets the NLRP3 inflammasome, with a recently expanded focus on diabetic macular edema, and an apelin receptor agonist (Azelaprag) positioned as an exercise mimetic for obesity. Despite a challenging history with withdrawn anemia (BGE-117) and terminated COVID-19 (BGE-175) trials, BioAge has pivoted to a more defined strategy emphasizing NLRP3 inhibition and metabolic rejuvenation. With a public listing (BIOA) and an estimated valuation of $800 million, BioAge represents a high-risk, high-reward opportunity in the longevity biotech space. Success hinges on advancing its NLRP3 program into the clinic and generating positive proof-of-concept data for Azelaprag in metabolic indications.

Upcoming Catalysts (preview)

• Q2 2026Initiation of clinical trial for NLRP3 inhibitor in diabetic macular edema35% success
• H2 2026Phase 2 start or proof-of-concept data for Azelaprag (apelin agonist) in obesity30% success
• TBDPotential partnership or licensing deal for NLRP3 or apelin programs40% success